UPDATE: Goldman Sachs Upgrades Emerson (EMR) to Buy
Goldman Sachs analyst Joe Ritchie upgraded Emerson (NYSE: EMR) from Neutral to Buy with a price target of $97.00 (from $89.00).
The analyst comments "We upgrade EMR to Buy from Neutral as we believe the company is set to benefit from improving oil & gas fundamentals, FactSet consensus estimates for 2021-2023 appear too low and the stock is inexpensive relative to coverage despite solid FCF, a healthy balance sheet and catalysts on the horizon. In our 2021 outlook, we highlighted that O&G could be the next long cycle end market (after commercial aero) to inflect. Since then, our Global Commodities Research team has pulled forward its Brent crude oil $65/bbl forecast to July 2021 (from December), with an expectation that this level will sustain through 2022. In this backdrop, we expect both sentiment and fundamentals to improve for oily industrials and we view EMR as one of the highest quality ways to invest in this theme in our space. While we expect the Energy complex to maintain stronger capital discipline in this O&G upcycle, our Global Energy team expects traditional capex to increase to $1.9bn/$12.2bn in 2021/2022 off of low levels (2020 was the lowest capex year in at least two decades). Historically, this has correlated well with Automation Solutions (AS) growth (GS: +6%/+5.5% in 2021/2022). Additionally, we think record levels of restructuring spend will likely drive strong adjusted EBIT margin expansion over the next two years."
Shares of Emerson closed at $82.75 yesterday.
You May Also Be Interested In
- Jefferies Downgrades Lear (LEA) and BorgWarner (BWA) to Hold and Upgrades Visteon (VC) to Buy
- Severn Trent Plc. (SVT:LN) (SVTRF) PT Lowered to GBP30 at HSBC
- Premier Investments Ltd. (PMV:AU) PT Lowered to AUD26.28 at Credit Suisse
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Hot Comments, Hot Upgrades, Upgrades
Related EntitiesGoldman Sachs, Crude Oil
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!